Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Maxmoeon Dec 02, 2024 9:25pm
91 Views
Post# 36341929

RE:RE:RE:RE:RE:RE:RE:Dept restructuring

RE:RE:RE:RE:RE:RE:RE:Dept restructuring
PWIB123 wrote: Forgive me.  I assumed you knew.  You can't trade around this stock.  There's literally no volume.  I'm stuck, like many others.  I'll do away with the mirrors once I know TH-1902 is not going to be the game changer we were all counting on, initially.  And I do have little faith at this point that anything significant is going to come of it.  Until then, it's $30 for me.  If and when that major pot hole breaks the final axle, I'll likely be taking tax losses against capital gains I'll create against real estate investments and move on.  

Maxmoe wrote: I suggest you remove your rear view mirror. And maybe the vanity mirror. Don't lose the focus out the windshield. Forget the $30 ancient history. Watch the path to $3.80 and watch out for another axle busting pot hole if there is one. Trade around it. 



Well good luck of course. We all win if you do that's for sure. New name for me. I haven't bought a Canadian pharma or biotech name for decades. Biochem Pharma . Forgive me shooter, I didn't realize you were holding $millions. I assumed 20-30-50,000 trading most days in Canada plus 10-20 in USA was enough. Maybe some steady good news will also increase liquidity. 
<< Previous
Bullboard Posts
Next >>